Creathor Ventures

What they fund

• Stage & Sector — Early-stage to expansion capital in biotechnology, industrial tech, and digital services [2].
• Geography — Primarily Germany and Switzerland, with historical investments in Scandinavia (e.g., Finland's Testdroid/Bitbar) [2][3].
• Check Size — Investments range from CHF 0.1m to CHF 7.5m, with a maximum considered investment of CHF 7.5m [2].
• Shape — Equity financing, often as lead or co-lead investor, targeting companies with strong international scalability potential [2].

Investment thesis

Creathor Ventures invests at the frontier of technology and science, targeting companies with the potential for international scalability and long-term growth [1]. The firm concentrates on high-barrier industries, specifically biotechnology (drug discovery and devices) and human capital services, while also backing tech companies advancing industrial automation and digitization [2]. Their strategy aligns investment timelines with the extended development cycles typical of deep-tech and biotech sectors [1]. They prioritize companies that can move beyond local market dominance to achieve global expansion [1]. Credibility: Creathor Ventures homepage and SECA member profile [1][2].

Value add

Creathor Ventures provides strategic support aligned with long-term growth, leveraging their 30+ years of experience in deep-tech and biotech [1]. They offer operational expertise in navigating complex regulatory and development cycles typical of life sciences [1].

Fit verdict: Ideal for founders in biotech, industrial tech, or deep-tech seeking patient capital and strategic guidance for international expansion.

Founder diligence script:

• What is your current runway and how does Creathor's typical follow-on posture support your next milestone?
• How does Creathor's network in Germany and Switzerland specifically accelerate your regulatory or market entry strategy?
• Can you share examples of how Creathor has helped portfolio companies navigate long development cycles?
• What is the expected decision timeline for a follow-on round in Series B or C?

Portfolio focus

• Tech & Industrial Automation — Companies like Allthings Technologies (tenant relationship management) and EchoRing by R3 (industrial radio networks) [1].
• Healthcare & Biotech — Heavy concentration in drug discovery and devices, including Phenex Pharmaceuticals and CryoTherapeutics [1].
• Human Capital & Services — Platforms like HeyJobs (talent platform for non-academic workforce) and Wunderflats (housing-as-a-service) [1].
• Genomics & Data — Blueprint Genetics (AI-enabled clinical genetic DNA testing) and Ledgy (equity management) [1][2].

Notable investments & exits

• ArchiMed buys Cube Biotech GmbH — Successful exit for Creathor Ventures in November 2021 [1].
• Testdroid (Bitbar) — Acquired by Google in 2014, following a $3M investment from Creathor in 2013 [3].
• IPOs — Over 20 companies have been listed on international stock exchanges over the past 30 years [2].

Strategic implications

Creathor's edge lies in its patient capital and deep expertise in long-cycle sectors like biotech and industrial tech, which many VCs avoid. Their strong presence in Germany and Switzerland provides a robust regional ecosystem, but their historical investments in Scandinavia (e.g., Finland) suggest a broader European reach that could be leveraged more aggressively. The signal to watch is their deployment pace in the current fund; a slowdown might indicate reserve constraints or a shift in strategy towards later-stage growth.

Where they could go further

Creathor could deepen its focus on AI-driven drug discovery, a high-growth sub-sector within life sciences where their expertise is highly relevant. Expanding their co-investment network in the US could help portfolio companies accelerate global expansion, particularly for biotech firms targeting FDA approval. Enhancing their post-investment support for commercialization could address a common gap for deep-tech companies moving from R&D to market.